Methods of tissue grafting, and more particularly methods for enhancing tissue graft revascularization, e.g., host engagement of pre-existing graft blood vessels.

Methods of tissue grafting, and more particularly methods for enhancing tissue graft revascularization, e.g., host engagement of pre-existing graft blood vessels.

The present disclosure provides compositions and methods for the treatment or prophylaxis of a perfusion disorder, such as ischemia and/or reperfusion injury, in a subject's organ, tissue or extremity by preserving or improving endothelial function, reducing vascular injury, and/or promoting vascular repair. The disclosed compositions comprise endothelial colony-forming cells or a serum-free composition comprising chemically defined media conditioned by endothelial colony-forming cells.

The present disclosure provides compositions and methods for the treatment or prophylaxis of a perfusion disorder, such as ischemia and/or reperfusion injury, in a subject's organ, tissue or extremity by preserving or improving endothelial function, reducing vascular injury, and/or promoting vascular repair. The disclosed compositions comprise endothelial colony-forming cells or a serum-free composition comprising chemically defined media conditioned by endothelial colony-forming cells.

Normal or genetically modified cell(s) having magnetic nanoparticle(s) bound (affixed) to their surfaces and methods of delivery to target tissues, e.g. For treatment of disease and/or injury.

The present disclosure relates to a scaffold with staircase microstructure for cell or tissue culture, comprising multiple layers. Each layer defines a plurality of through holes, and the through holes of each layer is in communication with a corresponding through holes of an adjacent layer. A method for culturing cell and tissue regeneration is also provided.

Provided are methods of isolating pericyte progenitor cells from pluripotent stem cells such as embryonic stem cells and induced pluripotent stem cells, by isolating CD105+, CD73+ and/or CD105+/CD73+ cells from embryoid bodies and optionally by enriching the cells with CD31− cells. Also provided are methods of isolating endothelial cells and co-derivation of pericyte and endothelial cells progenitor cells from embryoid bodies, and methods of differentiating same for various therapeutic applications. In addition, the invention provides an isolated pericyte progenitor cell having an expression marker signature of CD105+/CD73+CD31−/alpha SMA−/CD133−/Flk-1−.

The problem of the present invention is to provide a method of efficiently producing therapeutic alternative corneal endothelial cells, particularly, a method capable of stably producing them in a condition suitable for intraocular transplantation (in the anterior chamber) in a large amount. Furthermore, the present invention aims to provide a composition for transplantation, which is preferable for intraocular administration, particularly, into the anterior chamber. A therapeutic alternative corneal endothelial cell sphere can be produced by culturing stem cells in suspension in a differentiation induction medium containing a GSK3 inhibitor, retinoic acid and a ROCK inhibitor. Addition of a viscoelastic substance during intraocular (into the anterior chamber) transplantation of the sphere or cultured corneal endothelial cells dispersed into single cells can increase the number of adherent cells after transplantation.

Methods for generating human arterial endothelial cells under defined conditions in the absence of insulin are described. In particular, provided herein are efficient, defined, and scalable methods for generating human arterial endothelial cells from human pluripotent stem cells. Also provided herein are uses of human arterial endothelial cells obtained according to these methods. For example, methods of treating peripheral arterial disease and methods of screening agents for that effect adhesion of leukocytes to arterial endothelial cells are also provided.

Methods for generating human arterial endothelial cells under defined conditions in the absence of insulin are described. In particular, provided herein are efficient, defined, and scalable methods for generating human arterial endothelial cells from human pluripotent stem cells. Also provided herein are uses of human arterial endothelial cells obtained according to these methods. For example, methods of treating peripheral arterial disease and methods of screening agents for that effect adhesion of leukocytes to arterial endothelial cells are also provided.